



## Edluar receives FDA approval

The US Food and Drug Administration (FDA) has approved Edluar (formerly Sublinox) for the short-term treatment of insomnia. The product contains the well-known substance zolpidem and uses Orexo's patented sublingual tablet formulation. The collaboration agreement with Orexo entitles them to a milestone payment at FDA approval. That milestone is 5 MUSD based on the product labelling. No further milestone payments for Edluar are expected to be due Orexo. Product launch in the US is anticipated to start during 2nd half of 2009.

---

For more information contact:

Anders Larnholt, VP Investor Relations

Phone. +46 709 458 878

---

**MEDA AB (publ)** is a leading international specialty pharma company. The company specialises in marketing and pharmaceutical development in late clinical stage. Acquisitions and long-term partnerships drive the company's strategy. Meda is represented by its own organizations in about 40 countries. Meda's products are sold in 120 countries worldwide. The Meda share is listed under Large Cap on the Nasdaq OMX Nordic Stock Exchange in Stockholm. Find out more, visit [www.meda.se](http://www.meda.se).